Combining Mini-Mental State Examination and Montreal Cognitive Assessment for assessing the clinical efficacy of cholinesterase inhibitors in mild Alzheimer's disease: a pilot study.
Giovanna FurneriSimone VarrasiClaudia Savia GuerreraGiuseppe Alessio PlataniaVittoria TorreFrancesco Maria BoccaccioMaria Federica TestaFederica MartelliAlessandra PriviteraGrazia RazzaMario SantagatiSanto di NuovoConcetta PirroneSabrina CastellanoFilippo CaraciRoberto MonasteroPublished in: Aging clinical and experimental research (2024)
Current drugs for Alzheimer's Disease (AD), such as cholinesterase inhibitors (ChEIs), exert only symptomatic activity. Different psychometric tools are needed to assess cognitive and non-cognitive dimensions during pharmacological treatment. In this pilot study, we monitored 33 mild-AD patients treated with ChEIs. Specifically, we evaluated the effects of 6 months (Group 1 = 17 patients) and 9 months (Group 2 = 16 patients) of ChEIs administration on cognition with the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Frontal Assessment Battery (FAB), while depressive symptoms were measured with the Hamilton Depression Rating Scale (HDRS). After 6 months (Group 1), a significant decrease in MoCA performance was detected. After 9 months (Group 2), a significant decrease in MMSE, MoCA, and FAB performance was observed. ChEIs did not modify depressive symptoms. Overall, our data suggest MoCA is a potentially useful tool for evaluating the effectiveness of ChEIs.
Keyphrases
- depressive symptoms
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- mild cognitive impairment
- cognitive decline
- systematic review
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- mental health
- sleep quality
- machine learning
- multiple sclerosis
- patient reported outcomes
- big data
- working memory
- white matter